INDEX OF SUBJECTS FOR VOLUME 47

Abscesses
  microbiology of, 1075
Acanthamoeba spp.
  in human disease, 8
  isolation and identification, 9, 11
Acinetobacter spp.
  antibiotic resistance in hospitals, 1037
  epidemiology of aminoglycoside resistance, 455
Actinobacillus actinomycetemcomitans
  lipopolysaccharide, 569
  transport and isolation, 743
  two types of immune response in periodontitis, 569
Acyclic nucleoside phosphonates
  chemotherapy of DNA and retrovirus infections, 1
Adefovir
  antiviral activity, 1
Adenoviruses
  gastro-enteritis in children, 963
  infections in immunocompromised patients, 561
  typing, and epidemic keratoconjunctivitis, 91
Adherence
  group A streptococci to epithelial cells, 899
  H. pylori to gastric epithelial cells, 505
  inhibition by *L. acidophilus* biosurfactant, 1081
  MRSA to plastic and cell cultures, 705
  of nosocomial *S. marcescens* strains, 1105
  P. aeruginosa to tracheal cells, 129
  uropathogenic bacteria and yeasts to silicone rubber, 1081
Aeromonas spp.
  A. caviae type IV pilus, 527
  A. hydrophila collagen-binding protein, 417
  epidemiological typing of *A. hydrophila*, 499
Agglutination
  microplate test for Legionnaires' disease, 325
Aggregation
  properties of *M. catarrhalis*, 159
AIDS patients
  antibiotic susceptibility of associated mycoplasmas, 1115
  detection of mycoplasmas in respiratory tract specimens, 983
  haemolytic activity of *M. avium* isolates, 365
  JC virus infection in, 733
Amikacin
  resistance of Enterobacteriaceae, 1019
Aminoglycosides
  resistance of *Acinetobacter* spp., 455
  resistance of Enterobacteriaceae, 1019
Amoebae, 'free-living'
  human disease, 5
  isolation and identification, 5
  symbiosis with *Legionella* spp., 11, 937, 939
Anaerobes
  black-pigmented, and bacteriocin activity, 585
  in liver and spleen abscesses, 1075
Animals *see* Bite wounds, Guinea-pig model, Mouse model, Rat model
Antibiotic resistance
  aminoglycosides, and *Acinetobacter* spp., 455
  aminoglycosides, and Enterobacteriaceae, 1019
  extended-spectrum β-lactamases of *K. pneumoniae*, 201
  frequency of, 751
  gentamicin, and *S. aureus*, 173
  glycopeptide-resistant enterococci (GRE), 849
  in hospitals: surveillance and molecular typing, 1037
  House of Lords Select Committee report, 749, 751
  isoniazid, rifampicin and *M. tuberculosis*, 189
  macrolide-lincosamide, and *S. hyicus*, 63
  meropenem susceptibility of *P. aeruginosa*, 653
  methicillin and *S. aureus*, 341, 607, 705, 1037
  mupirocin, and *S. aureus*, 829
  overview of problems, 751
  rifampicin and *P. fluorescens*, 197
  role of education, 751
  of *S. aureus*, 341
  S. marcescens, 1105
  Soulsby report, 749
  S. pneumoniae causing invasive disease, 17
  surveillance, 751, 137
  vancomycin, and enterococci, 849
Antibiotics and other antimicrobial substances
  acyclic nucleoside phosphonates, 1
  animal bite wounds and, 95
  avoparcin, implications of use, 849
  chemoprophylaxis of outbreak strain of *N. meningitidis*, 993
  comparative susceptibilities of mycoplasmas, 1115
  current status and usage, 751
  drug metabolism in children, 975
  in induction of cytokine release by *S. aureus*, 533
  influence of gentamicin on growth of *L. monocytogenes*, 211
  in management of cystic fibrosis, 969
  natural susceptibility of *Providencia* spp., 629
  nebulised, 970
  penicillin in meningococcal disease, 961
  prospects for new agents, 751
  in surgical wound infection in Africa, 471
  susceptibility of *Nocardia* spp., 85
  therapy in children, 975
Antibodies
  against *A. actinomycetemcomitans*, 569
  against *B. burgdorferi*, 773
  against *C. pneumoniae*, 615
  against *H. pylori*, 1123
  against *P. aeruginosa*, 295
  against *S. aureus*, 217
  against *S. pilosicoli*, 317
  against streptococcal heat-shock proteins, 711
  anti-phosphatidylcholine, in brucellosis, 49
  see also Monoclonal antibodies
Antigens
  25-kDa OMP of *B. melitensis*, 39
  of *A. actinomycetemcomitans*, 569
  bacterial conjugate vaccines and, 563
  brucella, in diagnosis of brucellosis, 169
  copro-antigens of *Echinococcus* spp., 281
  of *M. hominis*, 659
  of *N. meningitidis*, 993
  outer-membrane, of *M. catarrhalis*, 159
  P. carinii, production in rat model, 543
  of *S. marcescens*, 1097
  of *S. pilosicoli*, 317
  of *S. pyogenes*, 655
Antiviral agents
  acyclic nucleoside phosphonates, 1
Apoptosis
  Y. enterocolitica-induced, 447
Arthritis, septic, 717
Astrovirus
  gastro-enteritis in children, 963
Atherosclerosis, 907
Avoparcin
  glycopeptide-resistant enterococci and, 849

Bactec system, 821
Bacteraemia
  F. odoratum, 183
  group B streptococci, 649
Bacteriophages
  for typing campylobacters, characterisation, 123
Bacteroides spp.
  enzyme production and genotoxicity, 407
  in liver and spleen abscesses, 1075
Balamuthia mandrillaris
  isolation of, 937, 939
BCG vaccine, 947
Bifidobacteria
  enzyme production and genotoxicity, 401
  protective role against necrotising enterocolitis, 391
Biliary tract infection in cryptosporidiosis, 71
Biofilms

formation by *C. albicans*, 253
growth of *G. vaginalis* and *L. acidophilus* in, 401
inhibition by biosurfactant, 1081
Sorbarod system, 401
Biosurfactant, 1081
Biotin
inhibition of enhanced toxin production by *C. difficile*, 767
Bite wounds
bacteriology, antimicrobial susceptibility and therapy, 95
Black-pigmented anaerobes
bacteriocin-like activity, 585
BOOK REVIEWS
Analytical Parasitology (edited by M. T. Rogan), 184
Antibiotic Resistance: Origins, Evolution, Selection and Spread (edited by D.J. Chadwick and J. Goode), 185
Bacteria in Biology, Biotechnology and Medicine, 4th edition (P. Singleton), 369
Cases in Medical Microbiology and Infectious Diseases, 2nd edition (P. H. Gilligan, M. L. Smiley and D. S. Shapiro), 843
CMV-Related Immunopathology (edited by M. Scholz, H. F. Rabenau, H. W. Doerr and J. Cinatl), 845
Current Clinical Topics in Infectious Diseases, volume 17 (edited by J. S. Remington and M. N. Swartz), 843
Infection and Environment (C. Kaplan), 844
Lecture Notes on Medical Microbiology (T. Elliott, M. Hastings and U. Desselberger), 185
Managing HIV (edited by G. Stewart), 369
Microbiology (T. J. J. Inglis), 369
Modeling Disease Transmission and Its Prevention by Disinfection (edited by C. J. Hurst), 185
Molecular and Diagnostic Procedures in Mycoplasmology Volume 1: Molecular Characterization (edited by S. Razin and J.G. Tully), 184
Molecular Genetics of Bacteria (L. Snyder and W. Champness), 844
Notes on Medical Virology, 11th edition (M. C. Timbury), 844
Tuberculosis Bacteriology: Organisation and Practice, 2nd edition (C. H. Collins, J. M. Grange and M. D. Yates), 843
Bordetella bronchiseptica
carbon source utilisation, 761
Borrelia burgdorferi
growth temperature ranges, 929
passive immunisation against infection, 773
Breast-feeding
HIV infection and, 945
Bronchiolitis, 957
Brucella spp.
ELISA for antigen detection, 169
immune response to 25-kDa OMP of *B. melitensis*, 39
Brucellosis
anti-phosphatidylcholine antibodies and, 49
Burkholderia spp.
B. cepacia, outer-membrane proteins, 999
B. cepacia, subspecific differentiation of cystic fibrosis isolates, 999
flagellin gene variation of *B. pseudomallei*, 689

Caffeine breath test, 976
Caliciviruses
gastro-enteritis in children, 963
Calymmatobacterium granulomatis
ultrastructural studies, 1069
CAMLiC system, 547
Campylobacters
characterisation of *C. coli* typing bacteriophages, 123
characterisation of *C. jejuni* typing bacteriophages, 123
C. jejuni, spirochaete-like movement, 521
infections in children, 958
mouse model of *C. jejuni* infection, 799
subtyping of *C. jejuni*, 353
Candida spp.
C. albicans, antifungal activity of IL-2-activated lymphocytes, 1007
C. albicans, biofilms and extracellular matrix, 253
C. albicans, phospholipase activity and virulence, 99
C. albicans, synergy of GM-CSF with fluconazole, 359
inhibition of adhesion by surlactin, 1081
interactions with platelets, 103
pathogenicity of *C. albicans*, 1047
pathogenicity of *C. krusei*, 1047
selective medium, 1027
use of CHROMagar for identification, 623
CAPD peritonitis, 265
Capnocytophaga ochracea
purification of immunosuppressive factor, 1087
Capsule
of group B streptococci, 717
of *S. marcescens*, 1097
of *S. pyogenes*, 655
Carbon source utilisation by *B. bronchiseptica*, 761
Cardiovascular disease, 907
Catheter-associated infections
F. odoratum, 183
Cell culture
adherence of *H. pylori* to gastric epithelial cells, 505
adherence of *P. aeruginosa* to tracheal cells, 129
adherence to and invasion of HEp-2 cells by group A streptococci, 899
differentiation of genogroups of *Ehrlichia*, 235
effect of conditions on adherence of MRSA, 705
persistence of *C. trachomatis* in U937 cells, 141
vacuolation of HeLa cells by *M. penetrans*, 915
Cervical cancer, 371
Chancroid, 1023
Children, infections in, 943
bacterial meningitis, 949, 957, 961
bronchiolitis, 957
classifying, in intensive care unit, 970
community acquired: epidemiology and surveillance, 955
comparison of incubation time and carrier state, 970
cystic fibrosis, management of chest infection, 969
dengue and other haemorrhagic fevers, 952
detection of *P. carinii*, 329
diphtheria, 953
drug metabolism and antibiotic therapy, 975
emerging and re-emerging, 950
epidemiological and public health perspectives, 947
gastrointestinal, 949, 958, 963
HIV, 943, 950
in immunocompromised individuals, 966
imported, 947
malaria, 948
measles, 950
meningococcal disease, 949, 961
tuberculosis, 954
viruses and gastro-enteritis, 963
Chlamydia
C. pneumoniae in atherosclerotic lesions, 907
C. pneumoniae, effects of gender and smoking on immune response, 441
C. trachomatis genital tract infection and infertility, 599
diagnosis of acute *C. pneumoniae* infection, 615
influence of interferon on *C. trachomatis* infection, 141
persistence of *C. trachomatis* in U937 cells, 141
Cholera, 847
Chondroitin sulphates
antiviral activity, 1015
CHROMagar
for yeast identification, 623
Cidofovir
antiviral activity, 1
Clostridia
C. difficile, inhibition of enhanced toxin production, 767
C. difficile toxin A binding to secretory component, 879
enzyme production and genotoxicity, 407
inhibition of growth by bifidobacteria, 391
in liver and spleen abscesses, 1075
pathogenicity in experimental necrotising enterocolitis, 391
promoter of *C. difficile* toxin B gene, 309
typing of environmental *C. difficile*, 117
Collagen-binding protein
of *A. hydrophila*, 417
Colon
bacterial enzyme production and genotoxicity, 407
Computerised surveillance, 958
Confocal laser scanning microscopy, 915
Copro-antigens of *Echinococcus* spp., 281
Corynebacterium urealyticum

selective medium for, 79
Cryptdins, 941
Cryptosporidium parvum
model of biliary tract infection, 71
Culture media
continuous automated mycobacterial liquid culture system (CAMLiC), 547
for diagnosis of chancroid, 1023
effect on adherence of MRSA, 705
effect of zinc on meropenem susceptibility of *P. aeruginosa*, 653
evaluation of systems for mycobacteria, 821
ground red hot pepper agar for *Candida* spp., 1027
inhibition of enhanced toxin production by *C. difficile*, 767
selective for *C. urealyticum*, 79
transport and isolation of *A. actinomycetemcomitans*, 743
use of CHROMagar for yeast identification, 623
viscosity, and motility of *C. jejuni*, 521
Cystic fibrosis, 129, 969, 999
Cytokines
antifungal activity, 1007
induction of release by *S. aureus*, 533
Cytomegalovirus
antiviral activity of antibacterial factors in human milk, 1015

Defensins, 941
Dengue, 952
Diarrhoea
C. jejuni infection in mouse model, 799
enteropathogenicity markers in *E. coli*, 781
heat-stable enterotoxin of *E. coli* (EAST-1), 889
pathogenicity of enteropathogenic *E. coli*, 283
viral gastro-enteritis in children, 963
Diphtheria, 953
DNA
characterisation of diarrhoeagenic *E. coli* clones, 227
epidemiological typing of *A. hydrophila*, 499
evaluation of *M. tuberculosis* growth by PCR, 933
identification of *Helicobacter* spp., 695
macrorestriction analysis of *K. pneumoniae*, 201
molecular analysis of *S. aureus* gentamicin resistance, 173
molecular epidemiology of aminoglycoside resistance in *Acinetobacter* spp., 455
molecular probes for detection of pathogenic fungi, 811
molecular typing of MRSA, 341
polymerase-based PCR amplification, effect of inhibitors, 1131
RAPD analysis of *A. hydrophila*, 499
Salmonella Enteritidis repeat element (SERE), 489
viruses, activity of acyclic nucleoside phosphonates, 1
see also Genes

Echinococcus spp.
importance of zoonotic infection, 281
vaccine, 281
Education
control of antimicrobial drug resistance, 751
Ehrlichiae
granulocytic ehrlichiosis, 475
taxonomy, 475
ultrastructural differentiation of genogroups, 235
Elderly patients, 649
Electron microscopy
C. albicans biofilms and extracellular matrix, 253
differentiation of genogroups of *Ehrlichia*, 235
persistence of *C. trachomatis* in U937 cells, 141
scanning, 253
transmission, 141
ultrastructure of *C. granulomatis*, 1069
ultrastructure of *H. trogontum*, 513
Electrophoresis
pulsed-field gel, 201, 341, 353, 659, 689, 993, 999
ELISA
antibody response in *S. aureus* septicaemia, 217
anti-phospholipid antibodies in brucellosis, 49
brucella antigen detection, 169
detection of copro-antigens of *Echinococcus* spp., 281
diagnosis of acute *C. pneumoniae* infection, 615
Endosymbiosis
of 'free-living' amoebae, 11, 937, 939
Enterobacteriaceae
aminoglycoside resistance in, 1019
Enterobacter spp.
E. aerogenes, antibiotic resistance in hospitals, 1037
E. cloacae, antibiotic resistance in hospitals, 1037
Enterococci
E. faecalis, inhibition of adhesion by surlactin, 1081
E. faecium, antibiotic resistance in hospitals, 1037
glycopeptide-resistant, 849
plasmids, 849
treatment of infections, 858
Enterohaemolysins
of *E. coli*, 1035
Enterotoxins
E. coli heat-stable (EAST-1), 889
S. aureus, 265, 335
Enzyme immunoassay
diagnosis of *C. pneumoniae* infection, 615
PCR-based, 615
Enzymes
bacterial production and genotoxicity in colon, 407
Epidemiology
aminoglycoside resistance in *Acinetobacter* spp., 455
characterisation of campylobacter-typing bacteriophages, 123
community-acquired paediatric infections, 955
Echinococcus spp., 281
genetic typing of *Salmonella* Enteritidis, 427
glycopeptide-resistant enterococci in hospitals, 854
HIV infection in children, 944
imported infections in children, 947
PCR-based typing of *A. hydrophila*, 499
plasmid profile analysis of *Salmonella* Typhimurium DT 204c, 483
P. multocida infections in pigs, 679
Salmonella Enteritidis repeat element (SERE), 489
serotype variation in '*S. milleri*' group, 435
subtyping of *C. jejuni*, 353
tracking antibiotic resistance in hospitals, 1037
typing of environmental *C. difficile* isolates, 117
typing of *Legionella* spp., 667
Escherichia coli
bactericidal activity of monoglycerides, 383
characterisation of diarrhoeagenic clones, 227
enteroaggregative (EAggEC), 889
enterohaemolysin production, 1035
enterohaemorrhagic (EHEC), 227, 1039
enteropathogenic (EPEC), 227, 283, 781
enteropathogenicity markers and diarrhoeal disease, 781
enzyme production and genotoxicity, 407
expressing 25-kDa OMP of *B. melitensis*, 39
haemolytic uraemic syndrome, 1039
heat-stable enterotoxin (EAST-1) and diarrhoea, 889
inhibition of adhesion by surlactin, 1081
in liver and spleen abscesses, 1075
pathogenicity in children, 283
role of serotype O157:H7 in human disease, 1039
verocytotoxigenic (VTEC), 1035
Exoenzymes
of *P. aeruginosa*, 303
Exotoxins
of coagulase-negative staphylococci, 577
of *S. pyogenes*, 655

Flagellin gene variation
of *B. pseudomallei*, 689
Flavobacterium odoratum
catheter-associated bacteraemia, 183
Fluconazole
synergy in candidacidal activity, 359
Fluid accumulation
Salmonella Typhimurium-induced, 151
Fungi
pathogenic, molecular probes for detection, 811
see also Specific fungi
Fusobacterium spp.
in liver and spleen abscesses, 1075

Gangliosides
antiviral activity, 1015
Gardnerella vaginosis
growth in Sorbarod biofilms, 401

Gastritis, 695, 863, 1123
Gastro-enteritis, viral, 963
Gastrointestinal infections
  in children, 949, 958
Gender
  immune response to *C. pneumoniae*, 441
Genes
  analysis of *C. difficile* toxin B promoter, 309
  detection of *S. aureus* toxin genes, 335
  emm gene sequence based on *S. pyogenes* subtyping, 893
  flagellin gene variation of *B. pseudomallei*, 689
  genetic differentiation of *P. multocida*, 679
  genotyping of hepatitis C virus, 643
  implications of genome sequencing, 375
  location of *S. aureus* mupirocin resistance gene, 829
  mutations in *erm*C translational attenuator, 63
Genital tract infection
  C. trachomatis and infertility, 599
Genital ulcer disease, 1023, 1069
Genome sequencing, 375
Genotoxicity
  enzyme production by intestinal bacteria, 407
Gentamicin
  influence on growth of *L. monocytogenes*, 211
  resistance of *S. aureus*, 173
Glycopeptides
  resistant enterococci, 849
Granulocyte-macrophage colony-stimulating factor
  in killing of *C. albicans*, 359
Granulocytic ehrlichiosis, 475
Granulomas
  role of IFN-γ in formation, 871
Guinea-pig model
  H. pylori gastritis, 1123

Haemolysins
  of coagulase-negative staphylococci, 577
  M. avium complex, 365
Haemolytic uraemic syndrome, 1039
Haemophilus spp.
  characterisation of non-capsulate *H. influenzae*, 1031
  H. ducreyi, laboratory diagnosis of chancroid, 1023
  H. ducreyi, sampling technique, 1023
  H. influenzae, genome sequencing, 375
  H. influenzae, paediatric meningitis, 957
  non-typable *H. influenzae*, P5 outer-membrane protein, 1059
Haemorrhagic fevers, 952
Heat-shock proteins
  of *S. pyogenes*, 711
Helicobacter spp.
  animal models of *H. pylori* gastritis, 863, 1123
  H. pylori, monoclonal antibody to inhibit adhesion, 505
  identification by PCR, 695
  immune response in *H. pylori* gastritis, 863, 1123
  ultrastructure of *H. trogontum*, 513
Hepatitis C virus
  distribution of genotypes in Korea, 643
Histophilus ovis
  characterisation by PCR methods, 987
  plasmid profile analysis, 987
HIV infection
  in children, 943, 950
  epidemiology, 944, 950
  vertical transmission, 944
Human papillomaviruses
  cervical cancer and, 371
  detection of, 371
Hydatidosis, 281
5-Hydroxytryptamine
  Salmonella Typhimurium-induced fluid accumulation and, 151

Immune response
  animal models of *H. pylori* gastritis, 863, 1123
  bacterial conjugate vaccines and, 563
  gender, smoking and *C. pneumoniae* infection, 441
  IFN-γ and granuloma formation, 871
  infections in immunocompromised children, 966
  neutrophils in *L. monocytogenes* infection, 55
  neutrophils in *Y. enterocolitica* infection, 55
  normal, 966
  to *A. actinomycetemcomitans* in periodontitis, 569
  to *B. melitensis* 25-kDa OMP, 39
  to *C. parvum* biliary tract infection, 71
  to heat-shock proteins in streptococcal diseases, 711
  to *S. pyogenes*, 655
Immunisation
  of HIV-infected patients, 947
  mice against *P. aeruginosa*, 295, 303
  passive, against Lyme disease spirochaetes, 773
Immunoassay
  detection of MRSA, 607
  PCR-based, 607
  see also Enzyme immunoassay
Immunocompromised patients
  causes of defects, 967
  infections in children, 966
  respiratory virus infections in, 561
Immunofluorescence assay
  diagnosis of acute *C. pneumoniae* infection, 615
  persistence of *C. trachomatis* in U937 cells, 141
Immunoglobulins
  binding of *C. difficile* toxin A to secretory IgA, 879
Immunohistochemistry
  detection of *C. pneumoniae*, 907
Immunosuppression
  pathogenicity of *C. krusei* and, 1047
  P. carinii infection in rat model, 543
Imported infections, 947, 955
Infection control
  antimicrobial drug resistance and, 751
  imported paediatric infections, 947, 955
  population movements and, 847
Infertility
  C. trachomatis infection and, 599
Inflammatory response
  to *H. pylori* infection, 1123
  to *M. avium* infection of gut mucosa, 725
Influenza viruses
  infections in immunocompromised patients, 561
  influenza A, effects of inhibitors in PCR amplification, 1131
Insertion sequence IS*200*
  profiles in *Salmonella*, 791
Intensive care units
  classifying infections: incubation time and carrier state, 970
  epidemiology of antibiotic resistance, 1037
  meningococcal disease and, 962
Interferon-γ
  in antifungal activity of IL-2-activated lymphocytes, 1007
  C. trachomatis infection and, 141
  role in granuloma formation, 871
Interleukins
  IL-2-activated lymphocytes, antifungal activity, 1007
  release of IL-8 from neutrophils, 55
International Health Regulations, 847
Intestinal loops
  Salmonella Typhimurium-induced fluid accumulation, 151
Intestinal microflora
  translocation and *C. difficile* infection, 591
Intestine, small
  peptide mediators of innate immunity, 941
Iron-binding proteins
  of *N. meningitidis*, 257, 757
Iso-electric focusing, 201
Isoniazid resistance
  in *M. tuberculosis*, 189

JC virus
  in African PML, 733

Kanamycin
  resistance of Enterobacteriaceae, 1019
Keratoconjunctivitis, epidemic, 91
Klebsiella pneumoniae
  antibiotic resistance in hospitals, 1037
  extended-spectrum β-lactamases, 201
  in liver and spleen abscesses, 1075

Labour, premature

associated with *M. hominis* infection, 179
β-Lactamases
extended-spectrum, of *K. pneumoniae*, 201
Lactobacilli
L. acidophilus, enzyme production and genotoxicity, 407
L. acidophilus, growth in Sorbarod biofilms, 401
L. acidophilus, inhibition of adhesion by surlactin, 1081
protective effect against *C. difficile* infection, 591
Lactoferrin
antistaphylococcal properties, 837
antiviral activity, 1015
Lectins
interactions with oral streptococci, 29
Legionella spp.
endosymbiosis and 'free-living' amoebae, 11, 937, 939
identification and epidemiological typing, 667
serological diagnosis of pneumonia, 325
Legionnaires' disease, 325
Leukoencephalopathy, progressive multifocal, 733
Lipopolysaccharide (LPS)
A. actinomycetemcomitans, 569
S. marcescens, 1097
Listeria monocytogenes
killing mechanism in activated macrophages, 211
neutrophil-mediated immune response, 55
Liver abscesses, microbiology, 1075
Louse-borne typhus, 847
Lyme disease, 773
Lymphocytes
function, and immunosuppressive factor of *C. ochracea*, 1087
IL-2-activated, antifungal activity, 1007
Lysozyme
antistaphylococcal properties, 837

Macrophages
candidacidal activity, 359
killing of *L. monocytogenes*, 211
Malaria, 948
Measles, 950
Media *see* Culture media
Meningitis
bacterial conjugate vaccine development, 563
H. influenzae type b, 957
improving outcomes in disease, 961
N. meningitidis, 949, 957, 961
paediatric imported infections, 949
S. pneumoniae infection, 17
Meningococci *see Neisseria meningitidis*
Meropenem
susceptibility of *P. aeruginosa*, 653
Methicillin-resistant *S. aureus*, 341, 607, 705, 1037
Micro-immunofluorescence assay
diagnosis of acute *C. pneumoniae* infection, 615
Microplate agglutination test
for Legionnaires' disease, 325
Milk, human
antibacterial factors with antiviral activity, 1015
binding of *C. difficile* to secretory component, 879
Monoclonal antibodies
against *Brucella* spp., 169
against *S. pilosicoli*, 317
against transferrin-binding proteins, 257
to inhibit adhesion of *H. pylori*, 505
Monocytes
candidacidal activity, 359
induction of cytokine release by *S. aureus*, 533
Monoglycerides
bactericidal activity, 383
Moraxella (Branhamella) catarrhalis
model of pulmonary clearance, 159
outer-membrane antigen expression, 159
Motility
of *C. jejuni*, 521
Mouse model
C. difficile and bacterial translocation, 591
C. jejuni infection, 799
C. parvum biliary tract infection, 71
C. trachomatis genital tract infection, 599
immune response in *H. pylori* gastritis, 863
immune response to *B. melitensis* 25-kDa OMP, 39
immunisation against *P. aeruginosa*, 295, 303
M. avium infection of gut mucosa, 725
pathogenicity of *C. albicans*, 99
protective effects of *S. boulardii*, 111
pulmonary clearance of *M. catarrhalis*, 159
role of IFN-γ in granuloma formation, 871
septic arthritis, group B streptococci, 717
Serpulina hyodysenteriae infection, 275
ultrastructural studies of *H. trogontum*, 513
Y. enterocolitica-induced thymocyte apoptosis, 447
M protein
of *S. pyogenes*, 655, 893
Mucosa
C. difficile and bacterial translocation, 591
mouse model of *M. avium* infection, 725
Mupirocin
resistance of *S. aureus*, 829
Muscle pain, orofacial, 577
Mycobacteria
diagnosis of isoniazid and rifampicin resistance in *M. tuberculosis*, 189
enhanced diagnosis of tuberculosis, 547
growth indicator tube evaluation, 821
haemolysin from *M. avium* strains from AIDS patients, 365
imported paediatric tuberculosis, 954
M. avium infection of mouse gut mucosa, 725
M. tuberculosis, evaluation of growth by PCR, 933
M. tuberculosis, IFN-γ in granuloma induction, 871
Mycoplasmas
AIDS-associated, 1115
antigenic and genomic variability of *M. hominis*, 659
comparative susceptibilities to antimicrobial agents, 1115
detection in AIDS patients by PCR, 983
human urogenital tract species, 1115
M. hominis infection and premature labour, 179
M. penetrans, protein kinase C activation, 915
M. penetrans, vacuolation of HeLa cells, 915
M. pneumoniae, antibiotic susceptibility, 1115
Mycoses
molecular probes for detection of pathogenic fungi, 811

Naegleria fowleri
in human disease, 6
isolation and identification, 7, 11
Natural killer cells, 1007
Necrosis
intestinal cells and *M. avium* infection, 725
Necrotising enterocolitis, 391
Neisseria spp.
carriage of an outbreak strain of *N. meningitidis*, 993
N. meningitidis, development of conjugate vaccines, 563
N. meningitidis, imported infections in children, 949
N. meningitidis, improving outcomes of disease, 961
N. meningitidis, infections in children, 961
N. meningitidis, transferrin-binding proteins, 257, 757
Neomycin
resistance of Enterobacteriaceae, 1019
Neonatal sepsis, 923
Neutrophils
candidacidal activity, 359
phagocytosis of *L. monocytogenes* and *Y. enterocolitica*, 55
release of interleukin-8, 55
Nocardia spp.
N. farcinica, identification and antibiotic susceptibility, 85
N. nova, identification and antibiotic susceptibility, 85
Nosocomial infections
catheter-associated *F. odoratum* bacteraemia, 183
epidemiology of resistance, 1037
S. marcescens, 1097, 1105

Oral infections
pathogenicity of *C. albicans* and *C. krusei*, 1047
see also Periodontitis
Orofacial muscle pain, 577
Oxacillin
in induction of cytokine release by *S. aureus*, 533
Oxygen metabolites
in killing of *L. monocytogenes*, 211

Paneth cell α-defensins, 941
Parainfluenza viruses
  infections in immunocompromised patients, 561
Pasteurella multocida
  genetic differentiation, 679
  porcine pneumonia and atrophic rhinitis, 679
PCR
  amplification of influenza A virus, 1131
  characterisation of diarrhoeagenic *E. coli* clones, 227
  characterisation of *Histophilus ovis*, 989
  characterisation of non-capsulate *H. influenzae*, 1031
  detection of *C. pneumoniae*, 907
  detection of mycoplasmas in respiratory tract specimens, 983
  detection of *P. carinii* infection, 329
  detection of *S. aureus* toxin genes, 335
  diagnosis of *C. pneumoniae* infection, 615
  effects of inhibitors in clinical specimens, 1131
  with enzyme immunoassay, 615
  epidemiological typing of *A. hydrophila*, 499
  ERIC, 227, 499
  evaluation of *M. tuberculosis* growth, 933
  flagellin gene variation of *B. pseudomallei*, 689
  genetic typing of *Salmonella* Enteritidis, 427
  genotyping of hepatitis C virus, 643
  identification of *Helicobacter* spp., 695
  identification of *Legionella* spp., 667
  with immunoassay for detection of MRSA, 607
  intergenic rRNA gene sequence length polymorphism analysis, 667
  molecular typing of MRSA, 341
  multiplex, 335, 607
  repetitive extragenic palindromic (REP), 1031
  ribotyping of *C. difficile*, 117
  Salmonella Enteritidis repeat element (SERE), 489
  tracking antimicrobial drug resistance in hospitals, 1037
Penicillin
  in meningococcal disease, 961
Peptides, antimicrobial, 941
Peptostreptococcus spp.
  in liver and spleen abscesses, 1075
  P. micros, pathogenic synergy with *Prevotella* spp., 135
  P. micros, virulence of rough and smooth morphotypes, 135
Periodontitis
  bacteriocin-like activity of black-pigmented anaerobes, 585
  immune response to *A. actinomycetemcomitans*, 569
  mechanisms of pathogenesis, 187
Peritonitis, 265
Phages *see* Bacteriophages
Phagocytosis
  L. monocytogenes and *Y. enterocolitica* by neutrophils, 55
Pharmacokinetics of antibiotics, 975
Phosphatidylcholine
  antibodies in brucellosis, 49
Phospholipase activity
  of *C. albicans*, 99
Pilus
  of *A. caviae*, 527
Plasmids
  aminoglycoside resistance of Enterobacteriaceae, 1019
  gentamicin resistance of *S. aureus*, 173
  glycopeptide resistance in enterococci, 849
  macrolide-lincosamide resistance of *S. hyicus*, 63
  profile analysis of *Histophilus ovis*, 989
  profile analysis of *Salmonella* Typhimurium DT 204c, 483
  rifampicin resistance in *P. fluorescens*, 197
Plastic
  adherence of MRSA, 705
Platelets
  interactions with *Candida* spp., 103
Pneumocystis carinii
  detection in children, 329
  progression of infection in rat model, 543
Pneumonia
  Legionnaires' disease, 325
  P. carinii, 329
  P. multocida infection in pigs, 679
  S. pneumoniae infection, 17
Polymerase chain reaction *see* PCR
Polysaccharides
  exopolysaccharides of *P. aeruginosa* in adherence, 129
Population movements
  infectious diseases and, 847
Porphyromonas gingivalis
  in adult periodontitis, 187
  bacteriocin-like activity, 585
  virulence factors, 187
Prevotella spp.
  in liver and spleen abscesses, 1075
  pathogenic synergy with *Pept. micros*, 135
  P. intermedia, bacteriocin-like activity, 585
  P. nigrescens, bacteriocin-like activity, 585
PROCEEDINGS OF THE PATHOLOGICAL SOCIETY OF GREAT BRITAIN AND IRELAND, 463, 1137
Prodigiosin production
  S. marcescens, 1105
Progressive atrophic rhinitis, 679
Proteins
  antimicrobial peptides, 941
  collagen-binding, of *A. hydrophila*, 417
  heat-shock, of *S. pyogenes*, 711
  M protein of *S. pyogenes*, 655, 893
  outer envelope, of *S. pilosicoli*, 317
  outer-membrane antigen of *B. melitensis*, 39
  outer-membrane, of *B. cepacia*, 999
  P5 outer-membrane, of non-typable *H. influenzae*, 1059
  protein kinase C activation and *M. penetrans*, 915
  transferrin-binding, of *N. meningitidis*, 257, 757
Providencia spp.
  natural antibiotic susceptibility, 629
Pseudomonas spp.
  immunisation of mice against *P. aeruginosa*, 295, 303
  P. aeruginosa, antibiotic resistance in hospitals, 1037
  P. aeruginosa in cystic fibrosis patients, 969
  P. aeruginosa, effects of exopolysaccharide on adherence, 129
  P. aeruginosa, exoenzyme vaccine, 303
  P. aeruginosa, meropenem susceptibility, 653
  P. fluorescens, plasmid, 197
  P. fluorescens, rifampicin resistance, 197
Pyrolysis mass spectrometry
  typing of *C. difficile* isolates, 117

Quails
  model of necrotising enterocolitis, 391

Rabies, 954
Rat model
  pathogenicity of *C. albicans* and *C. krusei*, 1047
  progression of *P. carinii* infection, 543
Red hot pepper agar, 1027
Respiratory syncytial virus
  antiviral activity of antibacterial factors in human milk, 1015
  infections in immunocompromised patients, 561
Respiratory tract infections
  chronic childhood: *P. carinii*, 329
  detection of mycoplasmas by PCR, 983
  diagnosis of acute *C. pneumoniae* infection, 615
  management in cystic fibrosis patients, 969
  pulmonary clearance of *M. catarrhalis*, 159
  viral, in immunocompromised patients, 561
  see also Specific disorders and organisms
Restriction endonuclease analysis
  genetic differentiation of *P. multocida*, 679
  subspecific differentiation of *B. cepacia*, 999
  typing of adenoviruses, 91
Restriction fragment length polymorphism analysis
  flagellin gene variation of *B. pseudomallei*, 689
  genotyping of hepatitis C virus, 643
  subtyping of *C. jejuni*, 353
Retrovirus infections
  chemotherapy, acyclic nucleoside phosphonates, 1
Reverse transcription, 1131
Rheumatic fever, 655
Ribotyping
  characterisation of diarrhoeagenic *E. coli* clones, 227
  genetic typing of *S.* Enteritidis, 427
  PCR, of *C. difficile*, 117
Rifampicin resistance
  in *M. tuberculosis*, 189

in *P. fluorescens*, 197
Rotavirus
infections in children, 958, 963

Saccharomyces boulardii
protective effect in immunosuppressed mice, 111
Salmonellae
genetic typing of serotype Enteritidis, 427
infections in children, 949, 958
serotype Eimsbuettel, IS*200* profile, 791
serotype Enteritidis repeat element (SERE), 489
serotype Livingstone, IS*200* profile, 791
serotype Typhimurium, plasmid profile analysis of DT 204c, 483
serotype Typhimurium, role of 5-hydroxytryptamine in fluid secretion, 151
SDS-PAGE
antigenic and genomic variability of *M. hominis*, 659
Secretory response
to *Salmonella* Typhimurium, 151
Sepsis
early onset neonatal, 923
speciation of viridans streptococci, 923
Septicaemia, *S. aureus*, 217, 265
Serology
detection of brucella antigen, 169
diagnosis of *C. pneumoniae* infection, 615
diagnosis of legionella pneumonia, 325
Serotyping
S. marcescens, 1097
'*S. milleri*' group, 435
S. pneumoniae causing invasive disease, 17
Serpulina spp.
S. hyodysenteriae murine model of infection, 275
S. pilosicoli diagnostic polyclonal and monoclonal antibodies, 317
Serratia marcescens
antibiotic resistance, 1105
O and K serotype distributions, 1097, 1105
virulence factors, 1105
Shigella spp.
infections in children, 949, 958
Silicone rubber
adhesion of uropathogenic bacteria and yeasts, 1081
Small round structural viruses, 963
Smoking
immune response to *C. pneumoniae* and, 441
Sorbarod biofilms, 401
Soulsby report, 749
Spirochaetes *see Borrelia burgdorferi*
Spleen abscesses, microbiology, 1075
Staphylococci
adherence to plastic and cell cultures, 705
in aetiology of chronic muscle pain, 577
antibody response in *S. aureus* septicaemia, 217
coagulase-negative, 577
gentamicin resistance of *S. aureus*, 173
haemolysins, 577
high-level mupirocin resistance in *S. aureus*, 829
macrolide-lincosamide resistance plasmid from *S. hyicus*, 63
methicillin-resistant *S. aureus* (MRSA), 341, 607, 705, 958, 1037
S. aureus, comparative phenotypic characterisation, 265
S. aureus in cystic fibrosis patients, 969
S. aureus, detection of toxin genes, 335
S. aureus, induction of cytokine release, 533
S. aureus, in liver and spleen abscesses, 1075
S. aureus, molecular typing, 341
S. aureus, nosocomial infections, 1037
S. aureus plasmids, 173
S. aureus, virulence factors, 265
S. epidermidis, antimicrobial synergy of lactoferrin and lysozyme, 837
S. epidermidis, inhibition of adhesion by surlactin, 1081
Streptococci
emm gene sequence based on *S. pyogenes* subtyping, 893
group A, adherence to and invasion of HEp-2 cells, 899
group B bacteraemia in the elderly, 649
group B capsular polysaccharides, 717
group D, in liver and spleen abscesses, 1075
heat-shock proteins of *S. pyogenes*, 711
interactions with lectins, 29
mouse model of septic arthritis, 717
serotyping of '*S. milleri*' group, 435
speciation of isolates from neonatal sepsis, 923
S. pneumoniae, antibiotic resistance, 17
S. pneumoniae, development of conjugate vaccines, 563
S. pneumoniae in invasive disease, 17
S. pyogenes rheumatic fever, 655
S. pyogenes virulence factors, 655
T-agglutination typing, 893
viridans, 923
Surgical wound infection in Africa, 471
Surlactin, 1081
Surveillance
antimicrobial drug resistance and, 751, 1037
community-acquired paediatric infections, 955
computerised systems, 958
nosocomial infections, 1037
Synergy
fluconazole in killing of *C. albicans*, 359
pathogenicity of *Prevotella* spp. and *Pept. micros*, 135

Taxonomy
characterisation of campylobacter typing bacteriophages, 123
ehrlichiae, 475
Temperature
growth ranges of *B. burgdorferi*, 929
Thermus spp.
DNA polymerases, 1131
Thymocytes
Y. enterocolitica-induced apoptosis, 447
Tick-borne diseases
granulocytic ehrlichiosis, 475
passive immunisation against Lyme disease spirochaetes, 773
Tobramycin
resistance of Enterobacteriaceae, 1019
Toxicity
of antibiotics in children, 976
Toxic shock syndrome toxin-1, 265, 335
Toxins
C. difficile toxins A and B, 309, 767, 879
toxic shock syndrome toxin-1, 265, 335
see also Enterotoxins, Exotoxins
Transferrin-binding proteins
of *N. meningitidis*, 257, 757
Translocation
mouse model of *C. difficile* infection, 591
Transport
of *A. actinomycetemcomitans*, 743
Travel
infectious diseases and, 847, 947
Trichomonas vaginalis
growth and survival, 555
Tuberculosis, 547, 954

Ultrastructural studies
Calymmatobacterium granulomatis, 1069
differentiation of genogroups of *Ehrlichia*, 235
H. trogontum, 513
Ureaplasma urealyticum
detection in specimens from AIDS patients, 983

Vaccines
against *Echinococcus* spp., 281
against measles, 950
against *N. meningitidis*, 563
against *P. aeruginosa*, 303
against *S. pneumoniae*, 563
bacterial conjugate, 563
role in control of infection, 751
Vaginosis, bacterial, 179, 401
Vancomycin-resistant enterococci, 849
Verocytotoxic *E. coli*, 1035
Vibrio cholerae
bactericidal activity of monoglycerides, 383
Virulence factors
A. caviae, 527
C. albicans, 99
enteropathogenic *E. coli*, 781

group A streptococci, 899
P. gingivalis, 187
S. aureus, 265
S. marcescens, 1105
S. pyogenes, 655
Vitamin A
HIV infection and, 945

Western blot analysis
identification of *S. pilosicoli*, 317
Wound infection
in Africa, 471

Xylitol
protective effect against *C. difficile* infection, 591

Yeasts
use of CHROMagar for identification, 623
Yersinia enterocolitica
induction of thymocyte apoptosis, 447
neutrophil-mediated immune response, 55

Zinc
meropenem susceptibility of *P. aeruginosa* and, 653
Zoonoses: hydatidosis, 281

INDEX OF AUTHORS FOR VOLUME 47

ABU-HASAN N *see* ADWAN *et al.*, 1019
ADWAN K, ABU-HASAN N, AL-ASMAR H. Analysis of neomycin, kanamycin, tobramycin and amikacin resistance mechanisms in gentamicin-resistant isolates of Enterobacteriaceae, 1019
AGOSTINI H T *see* STONER *et al.*, 733
AINSCOUGH S, KIBBLER C C. An evaluation of the cost-effectiveness of using CHROMagar for yeast identification in a routine microbiology laboratory, 623
ALA'ALDEEN D A *see* POWELL *et al.*, 257
AL-ASMAR H *see* ADWAN *et al.*, 1019
ALELJUNG P *see* STUREGÅRD *et al.*, 1123
ALEX ALEYAMMA *see* WEST *et al.*, 923
ALLISON D G *see* LIVESLEY *et al.*, 999
AL-SAIF N M, O'NEILL G L, MAGEE J T, BRAZIER J S, DUERDEN B I. PCR-ribotyping and pyrolysis mass spectrometry fingerprinting of environmental and hospital isolates of *Clostridium difficile*, 117
AL-SAWAN RIMA *see* WEST *et al.*, 923
AL-SHAMAHY H A, WRIGHT S G. Enzyme-linked immunosorbent assay for brucella antigen detection in human sera, 169
AL-WALI W I, ELVIN S J, MASON C M, CLARK A, TRANTER H S. Comparative phenotypic characteristics of *Staphylococcus aureus* isolates from line and non-line associated septicaemia, CAPD peritonitis, bone/joint infections and healthy nasal carriers, 265
AMAKO KAZUNOBU *see* SHIGEMATSU *et al.*, 521
ANDRADE J R C *see* ROSA *et al.*, 781
ANDREADIS T G *see* POPOV *et al.*, 235
AOKI T *see* SUGAWARA *et al.*, 871
APPUHAMY S, LOW J C, COOTE J G, PARTON R. PCR methods and plasmid profile analysis for characterisation of *Histophilus ovis* strains, 987
ARAKAWA M *see* OHYA *et al.*, 211
ARNOLD R, KÖNIG W. Interleukin-8 release from human neutrophils after phagocytosis of *Listeria monocytogenes* and *Yersinia enterocolitica*, 55
ASCENCIO F, WADSTRÖM T. A collagen-binding protein produced by *Aeromonas hydrophila*, 417
AUCKEN HAZEL M, PITT T L. Antibiotic resistance and putative virulence factors of *Serratia marcescens* with respect to O and K serotypes, 1105
AUCKEN HAZEL M, PITT T L. Different O and K serotype distributions among clinical and environmental strains of *Serratia marcescens*, 1097

BABIĆ D *see* STEPANOVIĆ *et al.*, 1027
BACK A *see* RAJASHEKARA *et al.*, 489
BAILLIE G S *see* HAWSER *et al.*, 253
BALDWIN T J. Pathogenicity of enteropathogenic *Escherichia coli*, 283
BAMBIRRA E A *see* PERET FILHO *et al.*, 111
BARRETT A *see* MAGEE *et al.*, 547
BARTELS H *see* NETTELNBREKER *et al.*, 141
BATEMA ROSANNE P *see* PETSCHOW *et al.*, 383
BAXTER A M *see* TEANPAISAN *et al.*, 585
BAXTER I A *see* LIVESLEY *et al.*, 999
BEALL B, FACKLAM R R, ELLIOTT J A, FRANKLIN A R, HOENES T, JACKSON D, LACLAIRE L, THOMPSON T, VISWANATHAN R. Streptococcal *emm* types associated with T-agglutination types and the use of conserved *emm* gene restriction fragment patterns for subtyping group A streptococci, 893
BEIGHTON D *see* WORKMAN *et al.*, 85
BEMIS D A *see* PLOTKIN AND BEMIS, 761
BENNETT-WOOD V R, CARAPETIS J R, ROBINS-BROWNE R M. Ability of clinical isolates of group A streptococci to adhere to and invade HEp-2 epithelial cells, 899
BENSAADA M *see* BUTEL *et al.*, 391
BERGH K *see* BEVANGER *et al.*, 993
BERMUDEZ L E *see* KIM *et al.*, 725
BERRY P *see* BRANGER *et al.*, 201
BETTELHEIM K A *see* GOLDWATER AND BETTELHEIM, 1039
BETTELHEIM K A. A spectrum of verocytotoxigenic *Escherichia coli*, 1035
BEVANGER L, BERGH K, GISNÅS G, CAUGANT D A, FRØHOLM L O. Identification of nasopharyngeal carriage of an outbreak strain of *Neisseria meningitidis* by pulsed-field gel electrophoresis *versus* phenotypic methods, 993
BHAT D A *see* DESHPANDE *et al.*, 365
BIRKELUND S *see* JENSEN *et al.*, 659
BISHOP K *see* POWELL *et al.*, 257
BISTONI F *see* TISSI *et al.*, 717
BLOIGU A *see* VON HERTZEN *et al.*, 441
BLOMQVIST L *see* COLQUE-NAVARRO *et al.*, 217
BOLLET C *see* DAVIN-REGLI *et al.*, 499
BOLTON F J *see* SAILS *et al.*, 123
BORCH K *see* TIVELJUNG *et al.*, 695
BOROVSKY Z, TARSHIS M, ZHANG P, ROTTEM S. Protein kinase C activation and vacuolation in HeLa cells invaded by *Mycoplasma penetrans*, 915
BORRIELLO S P *see* POWELL *et al.*, 257
BOWDEN R A, CLOECKAERT A, ZYGMUNT M S, DUBRAY G. Evaluation of immunogenicity and protective activity in BALB/c mice of the 25-kDa major outer-membrane protein of *Brucella melitensis* (Omp25) expressed in *Escherichia coli*, 39
BRANGER C, LESIMPLE A L, BRUNEAU B, BERRY P, LAMBERT-ZECHOVSKY N. Long-term investigation of the clonal dissemination of *Klebsiella pneumoniae* isolates producing extended-spectrum β-lactamases in a university hospital, 201
BRAZIER J S *see* AL-SAIF *et al.*, 117
BROOK I, FRAZIER E H. Microbiology of liver and spleen abscesses, 1075
BRUMMER E *see* NATARAJAN *et al.*, 359
BRUNEAU B *see* BRANGER *et al.*, 201
BRUN J *see* PETITJEAN *et al.*, 615
BUSSCHER H J *see* VELRAEDS *et al.*, 1081
BUTEL M J, ROLAND N, HIBERT A, POPOT F, FAVRE A, TESSEDRE A C, BENSAADA M, RIMBAULT A, SZYLIT O. Clostridial pathogenicity in experimental necrotising enterocolitis in gnotobiotic quails and protective role of bifidobacteria, 391
BUTT H L, DUNSTAN R H, McGREGOR N R, ROBERTS T K, ZERBES MARIANN, KLINEBERG I J. An association of membrane-damaging toxins from coagulase-negative staphylococci and chronic orofacial muscle pain, 577
BYRNE M E *see* WRIGHT *et al.*, 173

CALDERON DE LA BARCA ANNA MARIÁ *see* LEE *et al.*, 29
CAMARGOS ELIZABETH R S *see* MOURA *et al.*, 513
CARAGEORGIOU H *see* KOSTARA *et al.*, 555
CARAPETIS J R *see* BENNETT-WOOD *et al.*, 899
CARBON C *see* VERDON *et al.*, 71
CASAO M A, LEIVA J, DIAZ R, GAMAZO C. Anti-phosphatidylcholine antibodies in patients with brucellosis, 49
CASEWELL M W *see* WORKMAN *et al.*, 85
CASTRO ANGELA C D *see* LEMOS *et al.*, 711
CATAMO G *see* PICCOLOMINI *et al.*, 743
CAUGANT D A *see* BEVANGER *et al.*, 993
CHABANON G *see* MARTY *et al.*, 129
CHAI Y G *see* PARK *et al.*, 643
CHAMOREY E *see* DAVIN-REGLI *et al.*, 499
CHANDRASEKARAN S, LALITHAKUMARI D. Plasmid-mediated rifampicin resistance in *Pseudomonas fluorescens*, 197
CHAVAGNAT F *see* MARTY *et al.*, 129
CHEMIN K *see* MARTY *et al.*, 129
CHEN K-H *see* LIN *et al.*, 447
CHEN S-M *see* POPOV *et al.*, 235
CHEW W K, LASAITIS R M, SCHIO F A, GILBERT G L. Clinical evaluation of the Mycobacteria Growth Indicator Tube (MGIT) compared with radiometric (Bactec) and solid media for isolation of *Mycobacterium* species, 821
CHIN J C *see* DJORDJEVIC *et al.*, 679
CHRISTIANSEN G *see* JENSEN *et al.*, 659
CLARK A *see* AL-WALI *et al.*, 265
CLOECKAERT A *see* BOWDEN *et al.*, 39
COLMAN G, COOKE E M, COOKSON B D, COOPER P G,

EFSTRATIOU A, GEORGE R C. Pneumococci causing invasive disease in Britain 1982–1990, 17
COLONNA D'ISTRIA V *see* DAVIN-REGLI *et al.*, 499
COLQUE-NAVARRO P, SÖDERQUIST B, HOLMBERG H, BLOMQVIST L, OLCÉN P, MÖLLBY R. Antibody response in *Staphylococcus aureus* septicaemia – a prospective study, 217
CONNOR J D *see* PODDAR *et al.*, 1131
CONTINI C *see* CULTRERA *et al.*, 983
CONTINI C, PIA VILLA MARIA, ROMANI R, MEROLLA R, DELIA S, RONCHETTI R. Detection of *Pneumocystis carinii* among children with chronic respiratory disorders in the absence of HIV infection and immunodeficiency, 329
COOKE E M *see* COLMAN *et al.*, 17
COOKSON B D *see* COLMAN *et al.*, 17
COOKSON B D *see* WOODFORD *et al.*, 829
COOPER P G *see* COLMAN *et al.*, 17
COOTE J G *see* APPUHAMY *et al.*, 987
CORKILL J E *see* WINSTANLEY *et al.*, 689
CREMIEUX ANDREE *see* DAVIN-REGLI *et al.*, 499
CRIADO M T *see* PINTOR *et al.*, 757
CRICHTON PAMELA B, OLD D C, MORPHY HANNAH F. Distribution of insertion sequence IS*200* among different clonal lines of the related *Salmonella* serotypes Livingstone and Eimsbuettel, 791
CRIPPS A W *see* KYD *et al.*, 159
CRIPPS A W *see* WEBB AND CRIPPS, 1059
CULTRERA R, ROULLAND-DUSSOIX DAISY, ROMANI R, CONTINI C. Use of PCR to detect mycoplasma DNA in respiratory tract specimens from adult HIV-positive patients, 983
CURRAN R *see* TOWNER *et al.*, 607
CURRY A *see* SAILS *et al.*, 123
CURTIS S, WILKINSON G W G, WESTMORELAND D. An outbreak of epidemic keratoconjunctivitis caused by adenovirus type 37, 91
CUTLER C W *see* JOTWANI AND CUTLER, 187

DALLA-COSTA LIBERA M, IRINO KINUE, RODRIGUES J, RIVERA IRMA N G, TRABULSI L R. Characterisation of diarrhoeagenic *Escherichia coli* clones by ribotyping and ERIC-PCR, 227
DALLAS S D, ROLFE R D. Binding of *Clostridium difficile* toxin A to human milk secretory component, 879
DÄUBENER W *see* NETTELNBREKER *et al.*, 141
DAVIN-REGLI A, BOLLET C, CHAMOREY E, COLONNA D'ISTRIA V, CREMIEUX ANDREE. A cluster of infections due to *Aeromonas hydrophila* revealed by combined RAPD and ERIC-PCR, 499
DE CLERCQ E. Acyclic nucleoside phosphonates: a new dimension to the chemotherapy of DNA virus and retrovirus infections, 1
DE GRAAFF J *see* VAN DALEN *et al.*, 135
DE GRAAFF J *see* VAN DOORN *et al.*, 863
DE LA MAZA LUIS M *see* PAL *et al.*, 599
DELIA S *see* CONTINI *et al.*, 329
DESHPANDE R G, KHAN M B, BHAT D A, NAVALKAR R G. Haemolysin from *Mycobacterium avium* complex isolates from AIDS patients, 365
DIAZ R *see* CASAO *et al.*, 49
DI BONAVENTURA G *see* PICCOLOMINI *et al.*, 743
DICKSON T C *see* KIROV *et al.*, 527
DJORDJEVIC S P, EAMENS G J, HA H, WALKER M J, CHIN J C. Demonstration that Australian *Pasteurella multocida* isolates from sporadic outbreaks of porcine pneumonia are non-toxigenic (*toxA*$^-$) and display heterogeneous DNA restriction endonuclease profiles compared with toxigenic isolates from herds with progressive atrophic rhinitis, 679
DJUKIĆ S *see* STEPANOVIĆ *et al.*, 1027
DOI N *see* SUGAWARA *et al.*, 871
DOUGLAS C W I *see* TEANPAISAN *et al.*, 585
DOUGLAS L JULIA *see* HAWSER *et al.*, 253
DOURNES J-L *see* MARTY *et al.*, 129
DOYLE R J *see* LEE *et al.*, 29
DRAKE D *see* LEE *et al.*, 29
DRESES-WERRINGLOER U *see* NETTELNBREKER *et al.*, 141
DROBNIEWSKI F A, WILSON S M. The rapid diagnosis of isoniazid and rifampicin resistance in *Mycobacterium tuberculosis* – a molecular story, 189
DUBRAY G *see* BOWDEN *et al.*, 39
DUERDEN B I *see* AL-SAIF *et al.*, 117
DUMLER J S *see* POPOV *et al.*, 235
DUNSTAN R H *see* BUTT *et al.*, 577

EAMENS G J *see* DJORDJEVIC *et al.*, 679
EFSTRATIOU A *see* COLMAN *et al.*, 17
EIFUKU-KOREEDA HIROKO *see* INOUE *et al.*, 435
ELECTRICWALA QUDSIYA *see* WEST *et al.*, 923
ELLIOTT J A *see* BEALL *et al.*, 893
ELVIN S J *see* AL-WALI *et al.*, 265
ENDO T *see* SZÉNÁSI *et al.*, 5
EVANS R, JOSS A W L, PENNINGTON T H, HO-YEN D O. Progression of *Pneumocystis carinii* infection in an animal model, 543

FACKLAM R R *see* BEALL *et al.*, 893
FAUSER C *see* KAPPE *et al.*, 811
FAUST C *see* SONG AND FAUST, 309
FAVRE A *see* BUTEL *et al.*, 391
FENG H-M *see* POPOV *et al.*, 235
FERREIRÓS C M *see* PINTOR *et al.*, 757
FERRÓN L *see* PINTOR *et al.*, 757
FIRTH N *see* WRIGHT *et al.*, 173
FLUIT A C *see* VAN WAMEL *et al.*, 705
FONSECA M EVANGELINA F *see* MOURA *et al.*, 513
FONTANA R *see* LIGOZZI *et al.*, 933
FORD LORNA L *see* PETSCHOW *et al.*, 383
FOSTER H A *see* WEST *et al.*, 923
FOX A J *see* SAILS *et al.*, 123
FRANKLIN A R *see* BEALL *et al.*, 893
FRAZIER E H *see* BROOK AND FRAZIER, 1075
FREEMAN R *see* MAGEE *et al.*, 547
FRETIGNY M *see* PETITJEAN *et al.*, 615
FREYMUTH F *see* PETITJEAN *et al.*, 615
FRØHOLM L O *see* BEVANGER *et al.*, 993
FRY N K, HARRISON T G. An evaluation of intergenic rRNA gene sequence length polymorphism analysis for the identification of *Legionella* species, 667
FUJII BANYO *see* OUCHI *et al.*, 907
FUJIMOTO SHUJI *see* SHIGEMATSU *et al.*, 521
FUKUDA MINORU *see* OSAKI *et al.*, 505
FURUYA N *see* MATSUMOTO *et al.*, 295, 303
FURUYA N *see* TATEDA *et al.*, 325

GALLAGHER M J *see* WINSTANLEY *et al.*, 689
GALVIN J E *see* HUTTO *et al.*, 275
GAMAZO C *see* CASAO *et al.*, 49
GARRY L *see* VERDON *et al.*, 71
GASCON J *see* VILA *et al.*, 889
GENE A *see* VILA *et al.*, 889
GEORGE R C *see* COLMAN *et al.*, 17
GIAMBIAGI-DEMARVAL M *see* LEMOS *et al.*, 711
GILBERT G L *see* CHEW *et al.*, 821
GISNÁS G *see* BEVANGER *et al.*, 993
GIWERCMAN B *see* LIVESLEY *et al.*, 999
GLOCK C *see* PILLAY *et al.*, 1023
GOLDBLATT D. Recent developments in bacterial conjugate vaccines, 563
GOLDSTEIN ELLIE J C. New horizons in the bacteriology, antimicrobial susceptibility and therapy of animal bite wounds, 95
GOLDWATER P N, BETTELHEIM K A. New perspectives on the role of *Escherichia coli* O157:H7 and other enterohaemorrhagic *E. coli* serotypes in human disease, 1039
GOMES T A T *see* ROSA *et al.*, 781
GÓMEZ J A *see* PINTOR *et al.*, 757
GOODMAN J R *see* KIM *et al.*, 725
GORDON A *see* PORTELLI *et al.*, 1015
GORRINGE A R *see* POWELL *et al.*, 257
GOVAN J R W *see* LIVESLEY *et al.*, 999
GREENWOOD D. Lords a-leaping: the Soulsby report on antimicrobial drug resistance, 749
GREENWOOD D. Resistance to antimicrobial agents: a personal view, 751
GRODET A *see* VERDON *et al.*, 71
GRØNDAHL MARIE LOUISE, JENSEN GERDA M, NIELSEN C G, SKADHAUGE E, OLSEN J E, HANSEN M B. Secretory pathways in *Salmonella* Typhimurium-induced fluid accumulation in the porcine small intestine, 151

GUINAND M *see* MARTY *et al.*, 129
GULLOTTA F *see* STONER *et al.*, 733

HADDING U *see* SCHMITZ *et al.*, 335, 533
HA H *see* DJORDJEVIC *et al.*, 679
HALES B A *see* WINSTANLEY *et al.*, 689
HALL G *see* HODGSON *et al.*, 799
HALOUZKA J *see* HUBÁLEK *et al.*, 929
HAMPSON D J *see* TENAYA *et al.*, 317
HANNAN P C T. Comparative susceptibilities of various AIDS-associated and human urogenital tract mycoplasmas and strains of *Mycoplasma pneumoniae* to 10 classes of antimicrobial agent *in vitro*, 1115
HANSEN M B *see* GRØNDAHL *et al.*, 151
HAN VIOLET C *see* POPOV *et al.*, 235
HARRISON T G *see* FRY AND HARRISON, 667
HART C A *see* OGDEN *et al.*, 475
HART C A *see* WINSTANLEY *et al.*, 689
HART C A, SMYTH R L, DUERDEN B I. Infections in children: review, 943
HARTY D W S *see* WILLCOX *et al.*, 103
HAWSER S P, BAILLIE G S, DOUGLAS L JULIA. Production of extracellular matrix by *Candida albicans* biofilms, 253
HAYASHI H *see* YAMAKAWA *et al.*, 767
HEINZ H-P *see* SCHMITZ *et al.*, 335, 341, 533
HEROLDOVÁ M *see* HUBÁLEK *et al.*, 929
HEYMANN D L. Population movements and infectious diseases, 847
HIBERT A *see* BUTEL *et al.*, 391
HIRAKATA Y *see* MATSUMOTO *et al.*, 295, 303
HIRANO HIROSHI *see* OSAKI *et al.*, 505
HO B *see* STUREGARD *et al.*, 1123
HODGSON A E, McBRIDE B W, HUDSON M J, HALL G, LEACH S A. Experimental campylobacter infection and diarrhoea in immunodeficient mice, 799
HOENES T *see* BEALL *et al.*, 893
HOFMANN B *see* SCHMITZ *et al.*, 335, 341
HOIBY N *see* LIVESLEY *et al.*, 999
HOLMBERG H *see* COLQUE-NAVARRO *et al.*, 217
HOLTMANN H *see* NETTELNBREKER *et al.*, 141
HOOSEN A A *see* KHARSANY *et al.*, 1069
HOOSEN A A *see* PILLAY *et al.*, 1023
HO P L *see* SAMARANAYAKE *et al.*, 1047
HO-YEN D O *see* EVANS *et al.*, 543
HUANG K-J *see* LIN *et al.*, 447
HUBÁLEK Z, HALOUZKA J, HEROLDOVÁ M. Growth temperature ranges of *Borrelia burgdorferi sensu lato* strains, 929
HUDSON M J *see* HODGSON *et al.*, 799
HUI WEI *see* PAL *et al.*, 599
HUMPHREYS H *see* TOWNER *et al.*, 607
HUTTO D L, GALVIN J E, WANNEMUEHLER M J. Morphologic and temporal characterisation of lesions in an enhanced murine model of *Serpulina hyodysenteriae* infection, 275

IKENOUE T *see* SHIMADA *et al.*, 179
INOUE M, EIFUKU-KOREEDA HIROKO, KITADA K, TAKAMATSU-MATSUSHITA NOBUMI, OKADA YASUKO, OSANO E. Serotype variation in *Streptococcus anginosus*, *S. constellatus* and *S. intermedius*, 435
IRINO KINUE *see* DALLA-COSTA *et al.*, 227
ISHII Y *see* MATSUMOTO *et al.*, 295, 303
ISHII Y *see* TATEDA *et al.*, 325
ISHIKAWA I *see* NAKASHIMA *et al.*, 569
IWAKURA Y *see* SUGAWARA *et al.*, 871

JACKSON D *see* BEALL *et al.*, 893
JACQUE B *see* TRIVALLE *et al.*, 649
JENKINS D J. Hydatidosis – a zoonosis of unrecognised increasing importance?, 281
JENKS P J. Sequencing microbial genomes – what will it do for microbiology?, 375
JENSEN GERDA M *see* GRØNDAHL *et al.*, 151
JENSEN LISE T, THORSEN P, MØLLER B, BIRKELUND S, CHRISTIANSEN G. Antigenic and genomic homogeneity of successive *Mycoplasma hominis* isolates, 659
JEVON M *see* WOODFORD *et al.*, 829
JIMENEZ DE ANTA M T *see* VILA *et al.*, 889
JONASSON J *see* TIVELJUNG *et al.*, 695
JONES M E *see* SCHMITZ *et al.*, 341, 533
JONES YVETTE E *see* WRAY *et al.*, 483
JORDENS J ZOE. Characterisation of non-capsulate *Haemophilus influenzae* by repetitive extragenic palindromic (REP)-PCR, 1031
JOSS A W L *see* EVANS *et al.*, 543
JOTWANI R, CUTLER C W. Adult periodontitis – specific bacterial infection or chronic inflammation?, 187

KAMIYA S *see* OSAKI *et al.*, 505
KANAMOTO YASUO *see* OUCHI *et al.*, 907
KAPPE R, OKEKE C N, FAUSER C, MAIWALD M, SONNTAG H-G. Molecular probes for the detection of pathogenic fungi in the presence of human tissue, 811
KAPRIO J *see* VON HERTZEN *et al.*, 441
KARASAWA T *see* YAMAKAWA *et al.*, 767
KARITA MIKIO *see* OUCHI *et al.*, 907
KAWAKAMI HAYATO *see* OSAKI *et al.*, 505
KAZUMI Y *see* SUGAWARA *et al.*, 871
KENRI T *see* SHIMADA *et al.*, 179
KHAN M B *see* DESHPANDE *et al.*, 365
KHARSANY A B M, HOOSEN A A, NAICKER T, KIEPIELA P, STURM A W. Ultrastructure of *Calymmatobacterium granulomatis*: comparison of culture with tissue biopsy specimens, 1069
KIBBLER C C *see* AINSCOUGH AND KIBBLER, 623
KIEPIELA P *see* KHARSANY *et al.*, 1069
KIM S Y, GOODMAN J R, PETROFSKY MARY, BERMUDEZ L E. *Mycobacterium avium* infection of gut mucosa in mice associated with late inflammatory response and intestinal cell necrosis, 725
KIROV S M, SANDERSON K, DICKSON T C. Characterisation of a type IV pilus produced by *Aeromonas caviae*, 527
KITADA K *see* INOUE *et al.*, 435
KLINEBERG I J *see* BUTT *et al.*, 577
KODAMA Y *see* SHIMADA *et al.*, 179
KOEUTH T *see* RAJASHEKARA *et al.*, 489
KÖHLER L *see* NETTELNBREKER *et al.*, 141
KÖHRER K *see* SCHMITZ *et al.*, 335, 341
KÖNIG W *see* ARNOLD AND KÖNIG, 55
KOSEKI T *see* NAKASHIMA *et al.*, 569
KOSKENVUO M *see* VON HERTZEN *et al.*, 441
KOSTARA IONNA, CARAGEORGIOU H, VARONOS D, TZANNETIS S. Growth and survival of *Trichomonas vaginalis*, 555
KOTANI T *see* SHIMADA *et al.*, 179
KOTHAVADE R J, PANTHAKI M H. Evaluation of phospholipase activity of *Candida albicans* and its correlation with pathogenicity in mice, 99
KUO C-F *see* LIN *et al.*, 447
KURITA-OCHIAI T *see* OCHIAI *et al.*, 1087
KYD JENNELLE M, CRIPPS A W, MURPHY T F. Outer-membrane antigen expression by *Moraxella* (*Branhamella*) *catarrhalis* influences pulmonary clearance, 159

LACEY D E *see* LIVESLEY *et al.*, 999
LACLAIRE L *see* BEALL *et al.*, 893
LALITHAKUMARI D *see* CHANDRASEKARAN AND LALITHAKUMARI, 197
LAMBERT P A *see* LIVESLEY *et al.*, 999
LAMBERT T *see* SEWARD *et al.*, 455
LAMBERT-ZECHOVSKY N *see* BRANGER *et al.*, 201
LANDERAS ELENA, MENDOZA M CARMEN. Evaluation of PCR-based methods and ribotyping performed with a mixture of *Pst*I and *Sph*I to differentiate between strains of *Salmonella* serotype Enteritidis, 427
LANGE CARLA *see* SCHWARZ *et al.*, 63
LASAITIS R M *see* CHEW *et al.*, 821
LATORRE C *see* VILA *et al.*, 889
LEACH S A *see* HODGSON *et al.*, 799
LEE K O *see* PARK *et al.*, 643
LEE WHINGMING, CALDERON DE LA BARCA ANNA MARIÁ, DRAKE D, DOYLE R J. Lectin–oral streptococci interactions, 29
LEINONEN M *see* VON HERTZEN *et al.*, 441
LEITCH E C, WILLCOX M D P. Synergic antistaphylococcal properties of lactoferrin and lysozyme, 837
LEIVA J *see* CASAO *et al.*, 49
LEMELAND J F *see* TRIVALLE *et al.*, 649
LEMOS J A C, GIAMBIAGI-DEMARVAL M, CASTRO ANGELA C D. Expression of heat-shock proteins in *Streptococcus pyogenes* and their immunoreactivity with sera from patients with streptococcal diseases, 711

LESIMPLE A L *see* BRANGER *et al.*, 201
LIGOZZI M, PELOSI E, FONTANA R. Development of a rapid method for quantitative evaluation of *Mycobacterium tuberculosis* growth based on competitive polymerase chain reaction, 933
LIN Y-S, CHEN K-H, KUO C-F, HUANG K-J, WU J-J. Induction of thymocyte apoptosis in mice by *Yersinia enterocolitica* products, 447
LIU LI-PING *see* SHIH AND LIU, 773
LIVESLEY M A, BAXTER I A, LAMBERT P A, GOVAN J R W, WELLER P H, LACEY D E, ALLISON D G, GIWERCMAN B, HOIBY N. Subspecific differentiation of *Burkholderia cepacia* isolates in cystic fibrosis, 999
LOEFLER I J P. Surgical wound infection in the Third World: the African experience, 471
LOW J C *see* APPUHAMY *et al.*, 987
LOYKISSOONLAL D *see* PILLAY *et al.*, 1023
LUCAS S *see* STONER *et al.*, 733
LUPSKI J R *see* RAJASHEKARA *et al.*, 489

McBAIN A J, MACFARLANE G T. Ecological and physiological studies on large intestinal bacteria in relation to production of hydrolytic and reductive enzymes involved in formation of genotoxic metabolites, 407
McBRIDE B W *see* HODGSON *et al.*, 799
McCANCE D J. Human papillomaviruses and cervical cancer, 371
MACFARLANE G T *see* McBAIN AND MACFARLANE, 407
McGREGOR N R *see* BUTT *et al.*, 577
McLAREN I M *see* WRAY *et al.*, 483
MAGEE J G, FREEMAN R, BARRETT A. Enhanced speed and sensitivity in the cultural diagnosis of pulmonary tuberculosis with a continuous automated mycobacterial liquid culture (CAMLiC) system, 547
MAGEE J T *see* AL-SAIF *et al.*, 117
MAIWALD M *see* KAPPE *et al.*, 811
MARANGI M *see* TISSI *et al.*, 717
MÅRDH S *see* TIVELJUNG *et al.*, 695
MARIANO A T *see* ROSA *et al.*, 781
MARTEL P *see* TRIVALLE *et al.*, 649
MARTIN E *see* TRIVALLE *et al.*, 649
MARTY N, PASQUIER C, DOURNES J-L, CHEMIN K, CHAVAGNAT F, GUINAND M, CHABANON G, PIPY B, MONTROZIER H. Effects of characterised *Pseudomonas aeruginosa* exopolysaccharides on adherence to human tracheal cells, 129
MASON C M *see* AL-WALI *et al.*, 265
MATHEWS H L, WITEK-JANUSEK LINDA. Antifungal activity of interleukin-2-activated natural killer ($NK1.1^+$) lymphocytes against *Candida albicans*, 1007
MATSUMOTO T *see* TATEDA *et al.*, 325
MATSUMOTO T, TATEDA K, FURUYA N, MIYAZAKI S, OHNO A, ISHII Y, HIRAKATA Y, YAMAGUCHI K. Efficacies of alkaline protease, elastase and exotoxin A toxoid vaccines against gut-derived *Pseudomonas aeruginosa* sepsis in mice, 303
MATSUMOTO T, TATEDA K, MIYAZAKI S, FURUYA N, OHNO A, ISHII Y, HIRAKATA Y, YAMAGUCHI K. Effect of immunisation with *Pseudomonas aeruginosa* on gut-derived sepsis in mice, 295
MAY J T *see* PORTELLI *et al.*, 1015
MAZLÓ M *see* STONER *et al.*, 733
MENARD J F *see* TRIVALLE *et al.*, 649
MENDES E N *see* MOURA *et al.*, 513
MENDOZA M CARMEN *see* LANDERAS AND MENDOZA, 427
MEROLLA R *see* CONTINI *et al.*, 329
MIKELSAAR MARIKA *see* NAABER *et al.*, 591
MIKELSAAR R-H *see* NAABER *et al.*, 591
MITROVIĆ S *see* STEPANOVIĆ *et al.*, 1027
MITSUYAMA M *see* OHYA *et al.*, 211
MIYAZAKI S *see* MATSUMOTO *et al.*, 295, 303
MIZUNO S *see* SUGAWARA *et al.*, 871
MÖLLBY R *see* COLQUE-NAVARRO *et al.*, 217
MØLLER B *see* JENSEN *et al.*, 659
MONSTEIN H-J *see* TIVELJUNG *et al.*, 695
MONTROZIER H *see* MARTY *et al.*, 129
MORPHY HANNAH F *see* CRICHTON *et al.*, 791
MOURA SÍLVIA B, MENDES E N, QUEIROZ DULCIENE M M, CAMARGOS ELIZABETH R S, FONSECA M EVANGELINA F, ROCHA G A, NICOLI J R. Ultrastructure of *Helicobacter trogontum* in culture and in the gastrointestinal tract of gnotobiotic mice, 513
MUIR D, PILLAY D. Respiratory virus infections in immunocompromised patients, 561
MULI F W, STRUTHERS J K. The growth of *Gardnerella vaginalis* and *Lactobacillus acidophilus* in Sorbarod biofilms, 401
MURAKAMI H *see* TATEDA *et al.*, 325
MURPHY T F *see* KYD *et al.*, 159

NAABER P, MIKELSAAR R-H, SALMINEN S, MIKELSAAR MARIKA. Bacterial translocation, intestinal microflora and morphological changes of intestinal mucosa in experimental models of *Clostridium difficile* infection, 591
NAGAMINE Y *see* SHIMADA *et al.*, 179
NAGARAJA K V *see* RAJASHEKARA *et al.*, 489
NAGY ERZSÉBET *see* SZÉNÁSI *et al.*, 5
NAICKER T *see* KHARSANY *et al.*, 1069
NAKAMURA S *see* YAMAKAWA *et al.*, 767
NAKASHIMA K, USUI C, KOSEKI T, NISHIHARA T, ISHIKAWA I. Two different types of humoral immune response to *Actinobacillus actinomycetemcomitans* in high-responder periodontitis patients, 569
NAKAZAWA TERUKO *see* OUCHI *et al.*, 907
NAMAVAR F *see* VAN DOORN *et al.*, 863
NATARAJAN U, RANDHAWA N, BRUMMER E, STEVENS D A. Effect of granulocyte-macrophage colony-stimulating factor on candidacidal activity of neutrophils, monocytes or monocyte-derived macrophages and synergy with fluconazole, 359
NAVALKAR R G *see* DESHPANDE *et al.*, 365
NETTELNBREKER E, ZEIDLER H, BARTELS H, DRESES-WERRINGLOER U, DÄUBENER W, HOLTMANN H, KÖHLER L. Studies of persistent infection by *Chlamydia trachomatis* serovar K in TPA-differentiated U937 cells and the role of IFN-γ, 141
NEVILE S *see* RAJASHEKARA *et al.*, 489
NG H C *see* STUREGÅRD *et al.*, 1123
NICOLI J R *see* MOURA *et al.*, 513
NICOLI J R *see* PERET FILHO *et al.*, 111
NIELSEN C G *see* GRØNDAHL *et al.*, 151
NIETO EVA *see* ZAPARDIEL *et al.*, 79
NISHIHARA T *see* NAKASHIMA *et al.*, 569

OCHIAI K, SENPUKU H, KURITA-OCHIAI T. Purification of immunosuppressive factor from *Capnocytophaga ochracea*, 1087
ODHAV B *see* PILLAY *et al.*, 1023
OGDEN N H, WOLDEHIWET Z, HART C A. Granulocytic ehrlichiosis: an emerging or rediscovered tick-borne disease?, 475
OH M J *see* PARK *et al.*, 643
OHNO A *see* MATSUMOTO *et al.*, 295, 303
OHTAKI S *see* SHIMADA *et al.*, 179
OHTA T *see* YAMAKAWA *et al.*, 767
OHYA S, XIONG H, TANABE Y, ARAKAWA M, MITSUYAMA M. Killing mechanism of *Listeria monocytogenes* in activated macrophages as determined by an improved assay system, 211
OKADA YASUKO *see* INOUE *et al.*, 435
OKEKE C N *see* KAPPE *et al.*, 811
OLCÉN P *see* COLQUE-NAVARRO *et al.*, 217
OLD D C *see* CRICHTON *et al.*, 791
OLSEN J E *see* GRØNDAHL *et al.*, 151
O'NEILL G L *see* AL-SAIF *et al.*, 117
OREFICI GRAZIELLA *see* TISSI *et al.*, 717
OSAKI TAKAKO, YAMAGUCHI HIROYUKI, TAGUCHI HARUHIKO, FUKUDA MINORU, KAWAKAMI HAYATO, HIRANO HIROSHI, WATANABE SUMIO, TAKAGI ATSUSHI, KAMIYA SHIGERU. Establishment and characterisation of a monoclonal antibody to inhibit adhesion of *Helicobacter pylori* to gastric epithelial cells, 505
OSANO E *see* INOUE *et al.*, 435
OTOMO K *see* SUGAWARA *et al.*, 871
OUCHI KAZUNOBU, FUJII BANYO, KANAMOTO YASUO, KARITA MIKIO, SHIRAI MUTSUNORI, NAKAZAWA TERUKO. *Chlamydia pneumoniae* in coronary and iliac arteries of Japanese patients with atherosclerotic cardiovascular diseases, 907
OUELLETTE A J. Peptide mediators of innate immunity in the small intestine, 941
OWEN R J *see* SLATER AND OWEN, 353

PALMER H M *see* POWELL *et al.*, 257
PAL SUKUMAR, HUI WEI, PETERSON ELLENA M, DE LA MAZA LUIS M. Factors influencing the induction of infertility in a mouse model of *Chlamydia trachomatis* ascending genital tract infection, 599
PANIGRAHI D *see* WEST *et al.*, 923
PANTHAKI M H *see* KOTHAVADE AND PANTHAKI, 99
PAOLANTONIO MICHELE *see* PICCOLOMINI *et al.*, 743
PARISI LAURA *see* TISSI *et al.*, 717
PARK Y S, LEE K O, OH M J, CHAI Y G. Distribution of genotypes in the 5′ untranslated region of hepatitis C virus in Korea, 643
PARTON R *see* APPUHAMY *et al.*, 987
PASQUIER C *see* MARTY *et al.*, 129
PATEL SUNITA *see* WOODFORD *et al.*, 829
PELOSI E *see* LIGOZZI *et al.*, 933
PENHALE W J *see* TENAYA *et al.*, 317
PENNA F J *see* PERET FILHO *et al.*, 111
PENNINGTON T H *see* EVANS *et al.*, 543
PEREIRA A M S *see* ROSA *et al.*, 781
PERET FILHO L A, PENNA F J, BAMBIRRA E A, NICOLI J R. Dose effect of oral *Saccharomyces boulardii* treatments on morbidity and mortality in immunosuppressed mice, 111
PETERSON ELLENA M *see* PAL *et al.*, 599
PETERSSON F *see* TIVELJUNG *et al.*, 695
PETITJEAN J, VINCENT F, FRETIGNY M, VABRET A, POVEDA J D, BRUN J, FREYMUTH F. Comparison of two serological methods and a polymerase chain reaction-enzyme immunoassay for the diagnosis of acute respiratory infections with *Chlamydia pneumoniae* in adults, 615
PETROFSKY MARY *see* KIM *et al.*, 725
PETSCHOW B W, BATEMA ROSANNE P, TALBOTT R D, FORD LORNA L. Impact of medium-chain monoglycerides on intestinal colonisation by *Vibrio cholerae* or enterotoxigenic *Escherichia coli*, 383
PHILPOTT-HOWARD J *see* WORKMAN *et al.*, 85
PIA VILLA MARIA *see* CONTINI *et al.*, 329
PICCIANI C *see* PICCOLOMINI *et al.*, 743
PICCOLOMINI R, CATAMO G, DI BONAVENTURA G, PICCIANI C, PAOLANTONIO MICHELE. Laboratory and clinical comparison of preservation media and transport conditions for survival of *Actinobacillus actinomycetemcomitans*, 743
PILLAY A, HOOSEN A A, LOYKISSOONLAL D, GLOCK C, ODHAV B, STURM A W. Comparison of culture media for the laboratory diagnosis of chancroid, 1023
PILLAY D *see* MUIR AND PILLAY, 561
PINTOR M, GÓMEZ J A, FERRÓN L, FERREIRÓS C M, CRIADO M T. Analysis of TbpA and TbpB functionality in defective mutants of *Neisseria meningitidis*, 757
PIPY B *see* MARTY *et al.*, 129
PITT T L *see* AUCKEN AND PITT, 1097, 1105
PLOTKIN BALBINA J, BEM'S D A. Carbon source utilisation by *Bordetella bronchiseptica*, 761
PODDAR S K, SAWYER M H, CONNOR J D. Effect of inhibitors in clinical specimens on *Taq* and *Tth* DNA polymerase-based PCR amplification of influenza A virus, 1131
POLIANSKI JULIETTE *see* VERDON *et al.*, 71
POPOT F *see* BUTEL *et al.*, 391
POPOV V L, HAN VIOLET C, CHEN S-M, DUMLER J S, FENG H-M, ANDREADIS T G, TESH R B, WALKER D H. Ultrastructural differentiation of the genogroups in the genus *Ehrlichia*, 235
PORTELLI J, GORDON A, MAY J T. Effect of compounds with antibacterial activities in human milk on respiratory syncytial virus and cytomegalovirus *in vitro*, 1015
POVEDA J D *see* PETITJEAN *et al.*, 615
POWELL N B L, BISHOP K, PALMER H M, ALA'ALDEEN D A, GORRINGE A R, BORRIELLO S P. Differential binding of apo and holo human transferrin to meningococci and co-localisation of the transferrin-binding proteins (TbpA and TbpB), 257

QUEIROZ DULCIENNE M M *see* MOURA *et al.*, 513

RAJASHEKARA G, KOEUTH T, NEVILE S, BACK A, NAGARAJA K V, LUPSKI J R, KAPUR V. SERE, a widely dispersed bacterial repetitive DNA element, 489
RANDHAWA N *see* NATARAJAN *et al.*, 359
REID G *see* VELRAEDS *et al.*, 1081
RIMBAULT A *see* BUTEL *et al.*, 391
RIVERA IRMA N G *see* DALLA-COSTA *et al.*, 227
ROBERTS T K *see* BUTT *et al.*, 577
ROBINS-BROWNE R M *see* BENNETT-WOOD *et al.*, 899
ROCHA G A *see* MOURA *et al.*, 513
RODRIGUES J *see* DALLA-COSTA *et al.*, 227
ROLAND N *see* BUTEL *et al.*, 391
ROLFE R D *see* DALLAS AND ROLFE, 879
ROMANI R *see* CONTINI *et al.*, 329
ROMANI R *see* CULTRERA *et al.*, 983
RONCHETTI R *see* CONTINI *et al.*, 329
ROSA A C P, MARIANO A T, PEREIRA A M S, TIBANA A, GOMES T A T, ANDRADE J R C. Enteropathogenicity markers in *Escherichia coli* isolated from infants with acute diarrhoea and healthy controls in Rio de Janeiro, Brazil, 781
ROTTEM S *see* BOROVSKY *et al.*, 915
ROULLAND-DUSSOIX DAISY *see* CULTRERA *et al.*, 983
RYSCHKEWITSCH C F *see* STONER *et al.*, 733

SAIKKU P *see* VON HERTZEN *et al.*, 441
SAILS A D, WAREING D R A, BOLTON F J, FOX A J, CURRY A. Characterisation of 16 *Campylobacter jejuni* and *C. coli* typing bacteriophages, 123
SALMINEN S *see* NAABER *et al.*, 591
SAMARANAYAKE L P *see* SAMARANAYAKE *et al.*, 1047
SAMARANAYAKE Y H, WU P C, SAMARANAYAKE L P, HO P L. The relative pathogenicity of *Candida krusei* and *C. albicans* in the rat oral mucosa, 1047
SAMESHIMA H *see* SHIMADA *et al.*, 179
SANDERSON S M *see* KIROV *et al.*, 527
SASAKI T *see* SHIMADA *et al.*, 179
SAWYER M H *see* PODDAR *et al.*, 1131
SCHIO F A *see* CHEW *et al.*, 821
SCHMITZ F-J, STEIERT M, HOFMANN B, VERHOEF J, HADDING U, HEINZ H-P, KÖHRER K. Development of a multiplex-PCR for direct detection of the genes for enterotoxin B and C, and toxic shock syndrome toxin-1 in *Staphylococcus aureus* isolates, 335
SCHMITZ F-J, STEIERT M, TICHY H-V, HOFMANN B, VERHOEF J, HEINZ H-P, KÖHRER K, JONES M E. Typing of methicillin-resistant *Staphylococcus aureus* isolates from Düsseldorf by six genotypic methods, 341
SCHMITZ F-J, VERHOEF J, HADDING U, HEINZ H-P, JONES M E. Reduction in cytokine release from human monocytes by modifications in cell wall structure of *Staphylococcus aureus* induced by subinhibitory concentrations of oxacillin, 533
SCHWARZ S, LANGE CARLA, WERCKENTHIN CHRISTIANE. Molecular analysis of the macrolide-lincosamide resistance gene region of a novel plasmid from *Staphylococcus hyicus*, 63
SENPUKU H *see* OCHIAI *et al.*, 1087
SEWARD R J, LAMBERT T, TOWNER K J. Molecular epidemiology of aminoglycoside resistance in *Acinetobacter* spp., 455
SHIGEMATSU MIKA, UMEDA AKIKO, FUJIMOTO SHUJI, AMAKO KAZUNOBU. Spirochaete-like swimming mode of *Campylobacter jejuni* in a viscous environment, 521
SHIH CHIEN-MING, LIU LI-PING. Differential efficacy of passive immunisation against infection by Lyme disease spirochaetes transmitted by partially fed vector ticks, 773
SHIMADA M, KOTANI T, SAMESHIMA H, NAGAMINE Y, KODAMA Y, IKENOUE T, KENRI T, SASAKI T, OHTAKI S. Two patients with premature labour associated with *Mycoplasma hominis* infection, 179
SHIRAI MUTSUNORI *see* OUCHI *et al.*, 907
SJUNNESSON H *see* STUREGÅRD *et al.*, 1123
SKADHAUGE E *see* GRØNDAHL *et al.*, 151
SKURRAY R A *see* WRIGHT *et al.*, 173
SLATER E, OWEN R J. Subtyping of *Campylobacter jejuni* Penner heat-stable (HS) serotype 11 isolates from human infections, 353
SMYTH R L *see* HART *et al.*, 943
SÖDERQUIST B *see* COLQUE-NAVARRO *et al.*, 217
SONG K-P, FAUST C. Molecular analysis of the promoter region of the *Clostridium difficile* toxin B gene that is functional in *Escherichia coli*, 309
SONNTAG H-G *see* KAPPE *et al.*, 811
SORIANO F *see* ZAPARDIEL *et al.*, 79
STEIERT M *see* SCHMITZ *et al.*, 335, 341
STEPANOVIĆ S, DJUKIĆ S, VUKOVIĆ D, MITROVIĆ S, BABIĆ D. Ground red hot pepper agar in the isolation of yeasts of *Candida* spp., 1027
STEVENS D A *see* NATARAJAN *et al.*, 359

STOCK INGO, WIEDEMANN B. Natural antibiotic susceptibility of *Providencia stuartii*, *P. rettgeri*, *P. alcalifaciens* and *P. rustigianii* strains, 629
STOLLERMAN G H. The changing face of rheumatic fever in the 20th century, 655
STONER G L, AGOSTINI H T, RYSCHKEWITSCH C F, MAZLÓ M, GULLOTTA F, WAMUKOTA W, LUCAS S. Detection of JC virus in two African cases of progressive multifocal leukoencephalopathy including identification of JCV type 3 in a Gambian AIDS patient, 733
STRUELENS M J. Tracking the epidemiology of antimicrobial drug resistance in hospitals: time to deploy molecular typing, 1037
STRUTHERS J K *see* MULI AND STRUTHERS, 401
STUREGÅRD E, SJUNNESSON H, HO B, WILLÉN R, ALELJUNG P, NG H C, WADSTRÖM T. Severe gastritis in guinea-pigs infected with *Helicobacter pylori*, 1123
STURM A W *see* KHARSANY *et al.*, 1069
STURM A W *see* PILLAY *et al.*, 1023
SUGAWARA I, YAMADA H, KAZUMI Y, DOI N, OTOMO K, AOKI T, MIZUNO S, UDAGAWA T, TAGAWA Y, IWAKURA Y. Induction of granulomas in interferon-γ gene-disrupted mice by avirulent but not by virulent strains of *Mycobacterium tuberculosis*, 871
SURCEL H-M *see* VON HERTZEN *et al.*, 441
SZÉNÁSI ZSUZSANNA, ENDO T, YAGITA K, NAGY ERZSÉBET. Isolation, identification and increasing importance of 'free-living' amoebae causing human disease, 5
SZYLIT O *see* BUTEL *et al.*, 391

TAGAWA Y *see* SUGAWARA *et al.*, 871
TAGUCHI HARUHIKO *see* OSAKI *et al.*, 505
TAKAGI ATSUSHI *see* OSAKI *et al.*, 505
TAKAMATSU-MATSUSHITA NOBUMI *see* INOUE *et al.*, 435
TALBOT D C S *see* TOWNER *et al.*, 607
TALBOTT R D *see* PETSCHOW *et al.*, 383
TANABE Y *see* OHYA *et al.*, 211
TARSHIS M *see* BOROVSKY *et al.*, 915
TATEDA K *see* MATSUMOTO *et al.*, 295, 303
TATEDA K, MURAKAMI H, ISHII Y, FURUYA N, MATSUMOTO T, YAMAGUCHI K. Evaluation of clinical usefulness of the microplate agglutination test for serological diagnosis of legionella pneumonia, 325
TEANPAISAN R, BAXTER A M, DOUGLAS C W I. Production and sensitivity of bacteriocin-like activity among *Porphyromonas gingivalis*, *Prevotella intermedia* and *Pr. nigrescens* strains isolated from periodontal sites, 585
TENAYA I W M, PENHALE W J, HAMPSON D J. Preparation of diagnostic polyclonal and monoclonal antibodies against outer envelope proteins of *Serpulina pilosicoli*, 317
TESH R B *see* POPOV *et al.*, 235
TESSEDRE A C *see* BUTEL *et al.*, 391
THAKUR A *see* WILLCOX *et al.*, 103
THOMPSON T *see* BEALL *et al.*, 893
THORSEN P *see* JENSEN *et al.*, 659
TIBANA A *see* ROSA *et al.*, 781
TICHY H-V *see* SCHMITZ *et al.*, 341
TISSI LUCIANA, VON HUNOLSTEIN CHRISTINA, BISTONI F, MARANGI M, PARISI LAURA, OREFICI GRAZIELLA. Role of group B streptococcal capsular polysaccharides in the induction of septic arthritis, 717
TIVELJUNG ANNIKA, BORCH K, JONASSON J, MÅRDH S, PETERSSON F, MONSTEIN H-J. Identification of *Helicobacter* in gastric biopsies by PCR based on 16S rDNA sequences: a matter of little significance for the prediction of *H. pylori*-associated gastritis?, 695
TOWNER K J *see* SEWARD *et al.*, 455
TOWNER K J, TALBOT D C S, CURRAN R, WEBSTER C A, HUMPHREYS H. Development and evaluation of a PCR-based immunoassay for the rapid detection of methicillin-resistant *Staphylococcus aureus*, 607
TRABULSI L R *see* DALLA-COSTA *et al.*, 227
TRANTER H S *see* AL-WALI *et al.*, 265
TRIVALLE C, MARTIN E, MARTEL P, JACQUE B, MENARD J F, LEMELAND J F. Group B streptococcal bacteraemia in the elderly, 649
TZANNETIS S *see* KOSTARA *et al.*, 555

UDAGAWA T *see* SUGAWARA *et al.*, 871
UMEDA AKIKO *see* SHIGEMATSU *et al.*, 521
USUI C *see* NAKASHIMA *et al.*, 569

VABRET A *see* PETITJEAN *et al.*, 615
VAN DALEN P J, VAN DEUTEKOM-MULDER E C, DE GRAAFF J, VAN STEENBERGEN T J M. Pathogenicity of *Peptostreptococcus micros* morphotypes and *Prevotella* species in pure and mixed culture, 135
VAN DE BELT-GRITTER B *see* VELRAEDS *et al.*, 1081
VANDENBROUCKE-GRAULS C M J E *see* VAN WAMEL *et al.*, 705
VAN DER MEI H C *see* VELRAEDS *et al.*, 1081
VAN DEUTEKOM-MULDER E C *see* VAN DALEN *et al.*, 135
VAN DOORN N E M, VAN REES E P, NAMAVAR F, DE GRAAFF J. Local cellular immune response in the acute phase of gastritis in mice induced chemically and by *Helicobacter pylori*, 863
VAN REES E P *see* VAN DOORN *et al.*, 863
VAN STEENBERGEN T J M *see* VAN DALEN *et al.*, 135
VAN WAMEL W J B, VANDENBROUCKE-GRAULS C M J E, VERHOEF J, FLUIT A C. The effect of culture conditions on the in-vitro adherence of methicillin-resistant *Staphylococcus aureus*, 705
VARGAS M *see* VILA *et al.*, 889
VARONOS D *see* KOSTARA *et al.*, 555
VELRAEDS M M C, VAN DE BELT-GRITTER B, VAN DER MEI H C, REID G, BUSSCHER H J. Interference with initial adhesion of uropathogenic bacteria and yeasts to silicone rubber by a *Lactobacillus acidophilus* biosurfactant, 1081
VERDON R, POLIANSKI JULIETTE, GRODET A, GARRY L, CARBON C. *Cryptosporidium parvum* biliary tract infection in adult immunocompetent and immunosuppressed mice, 71
VERHOEF J *see* SCHMITZ *et al.*, 335, 341, 533
VERHOEF J *see* VAN WAMEL *et al.*, 705
VILA J, GENE A, VARGAS M, GASCON J, LATORRE C, JIMENEZ DE ANTA M T. A case-control study of diarrhoea in children caused by *Escherichia coli* producing heat-stable enterotoxin (EAST-1), 889
VINCENT F *see* PETITJEAN *et al.*, 615
VISWANATHAN R *see* BEALL *et al.*, 893
VON HERTZEN L, SURCEL H-M, KAPRIO J, KOSKENVUO M, BLOIGU A, LEINONEN M, SAIKKU P. Immune responses to *Chlamydia pneumoniae* in twins in relation to gender and smoking, 441
VON HUNOLSTEIN CHRISTINA *see* TISSI *et al.*, 717
VUKOVIĆ D *see* STEPANOVIĆ *et al.*, 1027

WADSTRÖM T *see* ASCENCIO AND WADSTRÖM, 417
WADSTRÖM T *see* STUREGÅRD *et al.*, 1123
WAGHORN D J *see* WOODFORD *et al.*, 829
WALKER D H *see* POPOV *et al.*, 235
WALKER M J *see* DJORDJEVIC *et al.*, 679
WAMUKOTA W *see* STONER *et al.*, 733
WANNEMUEHLER M J *see* HUTTO *et al.*, 275
WAREING D R A *see* SAILS *et al.*, 123
WATANABE SUMIO *see* OSAKI *et al.*, 505
WATSON A P *see* WOODFORD *et al.*, 829
WEBB B C *see* WILLCOX *et al.*, 103
WEBB DIANNE C, CRIPPS A W. Secondary structure and molecular analysis of interstrain variability in the P5 outer-membrane protein of non-typable *Haemophilus influenzae* isolated from diverse anatomical sites, 1059
WEBSTER C A *see* TOWNER *et al.*, 607
WELLER P H *see* LIVESLEY *et al.*, 999
WERCKENTHIN CHRISTIANE *see* SCHWARZ *et al.*, 63
WESTMORELAND D *see* CURTIS *et al.*, 91
WEST P W J, AL-SAWAN RIMA, FOSTER H A, ELECTRICWALA QUDSIYA, ALEX ALEYAMMA, PANIGRAHI D. Speciation of presumptive viridans streptococci from early onset neonatal sepsis, 923
WIEDEMANN B *see* STOCK AND WIEDEMANN, 629
WILKINSON G W G *see* CURTIS *et al.*, 91
WILLCOX M D P *see* LEITCH AND WILLCOX, 837
WILLCOX M D P, WEBB B C, THAKUR A, HARTY D W S. Interactions between *Candida* species and platelets, 103
WILLÉN *see* STUREGÅRD *et al.*, 1123
WILSON S M *see* DROBNIEWSKI AND WILSON, 189
WINSTANLEY C, HALES B A, CORKILL J E, GALLAGHER M J, HART C A. Flagellin gene variation between clinical and environmental isolates of *Burkholderia pseudomallei* contrasts with the invariance among clinical isolates, 689

WITEK-JANUSEK LINDA *see* MATHEWS AND WITEK-JANUSEK, 1007
WOLDEHIWET Z *see* OGDEN *et al.*, 475
WOODFORD N, WATSON A P, PATEL SUNITA, JEVON M, WAGHORN D J, COOKSON B D. Heterogeneous location of the *mupA* high-level mupirocin resistance gene in *Staphylococcus aureus*, 829
WOODFORD N. Glycopeptide-resistant enterococci: a decade of experience, 849
WORKMAN M R, PHILPOTT-HOWARD J, YATES M, BEIGHTON D, CASEWELL M W. Identification and antibiotic susceptibility of *Nocardia farcinica* and *N. nova* in the UK, 85
WRAY C, McLAREN I M, JONES YVETTE E. The epidemiology of *Salmonella* Typhimurium in cattle: plasmid profile analysis of definitive phage type (DT) 204c, 483
WRIGHT C L, BYRNE M E, FIRTH N, SKURRAY R A. A retrospective molecular analysis of gentamicin resistance in *Staphylococcus aureus* strains from UK hospitals, 173
WRIGHT S G *see* AL-SHAMAHY AND WRIGHT, 169
WU J-J *see* LIN *et al.*, 447
WU P C *see* SAMARANAYAKE *et al.*, 1047
XIONG H *see* OHYA *et al.*, 211

YAGITA K *see* SZÉNÁSI *et al.*, 5
YAMADA H *see* SUGAWARA *et al.*, 871
YAMAGUCHI HIROYUKI *see* OSAKI *et al.*, 505
YAMAGUCHI K *see* MATSUMOTO *et al.*, 295, 303
YAMAGUCHI K *see* TATEDA *et al.*, 325
YAMAKAWA K, KARASAWA T, OHTA T, HAYASHI H, NAKAMURA S. Inhibition of enhanced toxin production by *Clostridium difficile* in biotin-limited conditions, 767
YATES M *see* WORKMAN *et al.*, 85

ZAPARDIEL J, NIETO EVA, SORIANO F. Evaluation of a new selective medium for the isolation of *Corynebacterium urealyticum*, 79
ZEIDLER H *see* NETTELNBREKER *et al.*, 141
ZERBES MARIANN *see* BUTT *et al.*, 577
ZHANG P *see* BOROVSKY *et al.*, 915
ZYGMUNT M S *see* BOWDEN *et al.*, 39